TECHWIRE 30
(CIX: WRAL30)  1,193.64  down arrow-9.56  (-0.79 %)  Updated: 08:10 PM EST, Feb 27 2015
(NQ: Apple)  128.46  down arrow-1.96  (-1.5 %)  Updated: 08:10 PM EST, Feb 27 2015
(NY: QUINTILES)  64.98  up arrow+0.03  (0.05 %)  Updated: 06:40 PM EST, Feb 27 2015
(OP: BASF SE)  95.70  down arrow-1.55  (-1.59 %)  Updated: 05:20 PM EST, Feb 27 2015
(NQ: BioCryst)  10.20  down arrow-0.38  (-3.59 %)  Updated: 08:10 PM EST, Feb 27 2015
(NQ: BioDelivery)  15.00  up arrow+0.29  (1.94 %)  Updated: 08:10 PM EST, Feb 27 2015
(NQ: CEMP)  33.12  up arrow+1.07  (3.34 %)  Updated: 08:10 PM EST, Feb 27 2015
(NQ: Cisco Systems)  29.51  down arrow-0.4  (-1.34 %)  Updated: 08:10 PM EST, Feb 27 2015
(NQ: Cree)  39.26  down arrow-0.22  (-0.56 %)  Updated: 08:10 PM EST, Feb 27 2015
(NQ: DARA)  0.99  up arrow+0.05  (4.76 %)  Updated: 08:10 PM EST, Feb 27 2015
(NY: EMC CORPORATION)  28.94  up arrow+0.12  (0.42 %)  Updated: 06:40 PM EST, Feb 27 2015
(NQ: Extreme Networks)  3.55  up arrow+0.12  (3.5 %)  Updated: 08:10 PM EST, Feb 27 2015
(NQ: FB)  78.97  down arrow-1.44  (-1.79 %)  Updated: 08:10 PM EST, Feb 27 2015
(NY: GLAXOSMITHKLINE)  47.42  down arrow-0.42  (-0.88 %)  Updated: 06:40 PM EST, Feb 27 2015
(NQ: GOOG)  558.40  up arrow+2.92  (0.53 %)  Updated: 08:10 PM EST, Feb 27 2015
(NY: IBM)  161.94  up arrow+1.07  (0.67 %)  Updated: 06:40 PM EST, Feb 27 2015
(NY: LH)  123.03  down arrow-1.48  (-1.19 %)  Updated: 06:40 PM EST, Feb 27 2015
(OP: Lenovo Group)  30.58  up arrow+0.09  (0.3 %)  Updated: 05:20 PM EST, Feb 27 2015
(NY: MRK)  58.54  down arrow-0.42  (-0.71 %)  Updated: 06:40 PM EST, Feb 27 2015
(NQ: Microsoft Corp)  43.85  down arrow-0.21  (-0.47 %)  Updated: 08:10 PM EST, Feb 27 2015
(NQ: NTAP)  38.65    (0 %)  Updated: 08:10 PM EST, Feb 27 2015
(NY: NOVARTIS AG)  102.40  down arrow-0.6  (-0.58 %)  Updated: 06:40 PM EST, Feb 27 2015
(OP: Novozymes A/S)  48.99  down arrow-0.16  (-0.33 %)  Updated: 05:20 PM EST, Feb 27 2015
(NY: PFIZER)  34.32  down arrow-0.27  (-0.78 %)  Updated: 06:40 PM EST, Feb 27 2015
(NQ: Pozen)  7.33  down arrow-0.11  (-1.48 %)  Updated: 08:10 PM EST, Feb 27 2015
(NY: RED HAT)  69.12  down arrow-0.28  (-0.4 %)  Updated: 06:40 PM EST, Feb 27 2015
(NQ: BBRY)  10.81  up arrow+0.05  (0.46 %)  Updated: 08:10 PM EST, Feb 27 2015
(NQ: Salix)  157.20  up arrow+0.25  (0.16 %)  Updated: 08:10 PM EST, Feb 27 2015
(NQ: SQI)  17.41  down arrow-0.17  (-0.97 %)  Updated: 08:10 PM EST, Feb 27 2015

Posts tagged “Video game industry”

Updated November 2, 2007

Premium Lock BioDelivery Sciences Moves HQ to Raleigh

BDSI Move to larger space made to accommodate more employees, company says.

Updated November 1, 2007

Premium Lock BioDelivery Sciences Files Application for Acute Pain Treatment

BDSI Morrisville-based company seeks FDA approval for ‘breakthrough cancer pain.’ BDSI hopes to launch sales in 2008.

September 10, 2007

Premium Lock BioDelivery Sciences to Pay $7M for Ownership of Drug Delivery technology

BDSI RTP-based firm buys all U.S. rights to oral delivery method from QLT USA.

Updated September 5, 2007

Premium Lock What a Relief: BDSI Lands $60M Deal for Rights to Cancer Pain Reliever

 Europe-based Meda pays Morrisville drug development firm $30M up front for North America rights. Meda had already secured European rights.

Updated July 3, 2007

Premium Lock Application Process for Cancer Drug on Target

BioDelivery Sciences International announced Monday that its June 28 pre-NDA meeting with the U.S. Food and Drug Administration regarding the company’s Phase III BEMA Fentanyl product went according to plan.

April 26, 2007

Premium Lock BioDelivery Sciences Stock Soars 30% on Positive Drug Trial News

BDSI Triangle-based drug development firm reports effectiveness in use of breakthrough pain killer.

Updated April 10, 2007

Premium Lock Drug Firm BDSI Names Marketing Executive

BDSI Al Medwar, who once worked for Triangle Pharmaceuticals, joins BDSI from EMD Pharmaceuticals.

August 31, 2006

Premium Lock Contract Dispute Breaks Out Between BioDelivery Sciences, One Of Its Investors

Morrisville-based BDSI says Clinical Development Capital sought to acquire rights to drug delivery technology now under trial. CDC seeks to terminate $7M investment.

August 4, 2006

Premium Lock BioDelivery Sciences Lands European Partner For Pain Drug Delivery System

Morrisville-based pharmaceutical company to receive $2.5 million upfront payment. BDSI also secures rights to delivery system in Europe, U.S. markets.

June 9, 2006

Premium Lock BioDelivery Sciences International To Review Strategy for Nausea Drug

FDA spells out possible ways for company to win marketing approval. BDSI to evaluate costs, time needed for additional testing.

May 17, 2006

Premium Lock BioDelivery Sciences Converts Stocks to $7 Million in Cash From Investor

Drug development firm is testing means of delivering powerful pain reliever through oral patch.

March 1, 2006

Premium Lock FDA Rejects Anti-Nausea Drug Licensed by BioDelivery Sciences

CEO says he is 'surprised and disappointed' by the FDA decision. BDSI is seeking a meeting to discuss findings.

January 9, 2006

Premium Lock BDSI Aims for $250 Million in Sales With New Painkiller

Morrisville-based drug development firm files investigational new drug application with FDA for treatment of moderate to severe pain.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith